Aligos Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 |
| Research and development | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M |
| Operating expenses | $90.2M | $93.1M | $103.7M | $111.5M | $132.7M |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M |
| Pretax income | -$23.9M | -$130.9M | -$86.9M | -$95.9M | -$128.2M |
| Income tax expense | $314,000 | $331,000 | $795,000 | $106,000 | $143,000 |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M |
| Balance Sheet | |||||
| Cash and equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M |
| Current assets | $82.9M | $62.1M | $141.1M | $133.5M | $204.4M |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M |
| Current liabilities | $21.2M | $21.7M | $23.9M | $33.1M | $39.0M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M |
| Stockholders' equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M |
| Depreciation and amortization | $930,000 | $1.0M | $1.6M | $2.3M | $3.0M |
| Stock-based compensation | $5.0M | $8.5M | $12.7M | $14.7M | $13.5M |
| Capital expenditure | — | $130,000 | $19,000 | $943,000 | $892,000 |
| Free cash flow | — | -$80.9M | -$79.0M | -$80.3M | -$116.6M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 6.2M · Free float 71.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.